Rating
Buy
Price target
$480
Previous
$540
Implied upside
+24%

Mizuho analyst Vijay Rakesh lowered the price target on Tesla (NASDAQ: TSLA) to $480.00 (from $540.00) while maintaining a Outperform rating.

TSLA reported Rev/EPS of $22.4B/$0.41 (above cons. $22.1B/$0.35).

Main takeaways: 1) Slowing EV Demand growth in 2026E (we est EV LVP up ~4% y/y) after 2025 up ~30% y/y, 2) Auto GM ex-credits at 19.2% (up 120bps q/q), better with tariff relief/warranty writedowns, 2) TSLA cybercab now in production with cumulative cybercab miles reaching 1.7M, while FSD unsupervised launch targeted for 2H26E, 3) Optimus production ramping for internal testing in 2H26E, targeting commercial launch in 2027E, and 4) AI investment – F26E Capex guided $25B (prior $20B vs.

F25 at ~$9B) with 6 factories being built/switched, AI5 taped out with previously disclosed SOP in 2027E and planning to utilize INTC (Neutral, $60PT) 14A nodes.

Maintain Outperform, Lower Ests and PT to $480 (prior $540) as we see TSLA well-positioned leading physical AI with Cybercab/FSD traction, humanoid longer term, offset by near-term demand headwinds.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.